MiniMed Group, Inc. (MMED) Financial Statements

MiniMed Group, Inc. (MMED) reported trailing twelve-month revenue of $3.2B (up 14.3% year on year) and net income of -$309.0M as of 2026-07-31, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$316.0M.

Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason

MMEDMiniMed Group, Inc.Follow MMED — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 5.2B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 16 Nov, in 23 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jul 26.

Line	FY2024 Apr 24	FY2025 Apr 25	FY2026 Apr 26	TTM Jul 26
Revenue	2.47	2.72	3.10	3.22
Gross profit	1.44	1.53	1.68	1.74
Research & development	0.44	0.44	0.45	0.44
Operating income	-0.07	-0.15	-0.19	-0.17
Pre-tax income	-0.07	-0.15	-0.19	-0.17
Income tax	0.04	0.05	0.13	0.13
Net income	-0.11	-0.21	-0.33	-0.31
Diluted EPS ($)	-0.44	-0.84	-1.30	-1.22
Diluted shares (bn)	0.253	0.253	0.257	—

USD billions · SEC XBRL

MiniMed Group, Inc. — questions

What is MiniMed Group, Inc.'s revenue?: $3.2B over the twelve months to 2026-07-31, up 14.3% year on year, from its 10-Q and 10-K filings.
What is MiniMed Group, Inc.'s net income?: -$309.0M over the twelve months to 2026-07-31.
What is MiniMed Group, Inc.'s free cash flow?: -$316.0M over the twelve months to 2026-07-31.
What are MiniMed Group, Inc.'s diluted earnings per share?: $-1.22 over the twelve months to 2026-07-31.

Every figure on this page comes from MiniMed Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.